riner 聴nkontinansta Deerlendirme, Tan脹 Testleri ve Y旦netim-Prof. Dr. Omer L...Omer Lutfi Tapisiz
油
Her iki kad脹ndan biri (%50) hayatlar脹n脹n bir d旦neminde 端riner inkontinans脹 deneyimlemektedir. Kad脹nlarda semptomatik 端riner inkontinans g旦r端lme s脹kl脹脹 %25-61 aras脹nda deimekte olup bu oran >65 ya olan kad脹nlarda y端zde ellinin 端zerine 巽脹kmaktad脹r. G旦r端ld端端 端zere kad脹nlarda 端riner inkontinans; hayat kalitesini ciddi derecede etkileyen, s脹k g旦r端len bir toplum sal脹脹 sorunudur.
Bu sunumda kad脹nlarda 端riner inkontinansta deerlendirme, tan脹 testleri ve y旦netim konusu her y旦n端 ile ele al脹nacakt脹r. Prof. Dr. Omer Lutfi TAPISIZ
riner 聴nkontinansta Deerlendirme, Tan脹 Testleri ve Y旦netim-Prof. Dr. Omer L...Omer Lutfi Tapisiz
油
Her iki kad脹ndan biri (%50) hayatlar脹n脹n bir d旦neminde 端riner inkontinans脹 deneyimlemektedir. Kad脹nlarda semptomatik 端riner inkontinans g旦r端lme s脹kl脹脹 %25-61 aras脹nda deimekte olup bu oran >65 ya olan kad脹nlarda y端zde ellinin 端zerine 巽脹kmaktad脹r. G旦r端ld端端 端zere kad脹nlarda 端riner inkontinans; hayat kalitesini ciddi derecede etkileyen, s脹k g旦r端len bir toplum sal脹脹 sorunudur.
Bu sunumda kad脹nlarda 端riner inkontinansta deerlendirme, tan脹 testleri ve y旦netim konusu her y旦n端 ile ele al脹nacakt脹r. Prof. Dr. Omer Lutfi TAPISIZ
This document presents findings on fertility outcomes in women with endometriosis and adenomyosis, emphasizing that endometriosis does not significantly impact ovarian response or oocyte quality. Studies indicate nearly identical live birth rates for IVF cycles in women with endometriosis compared to controls, with various factors influencing success rates. Additionally, specific protocols for endometrial preparation in frozen embryo transfers show varying outcomes, stressing the importance of treatment approaches tailored to individual patient conditions.
The document discusses postmenopausal endometriosis, including its incidence, diagnostic challenges, and management strategies. It highlights the risks of cancer associated with endometriosis and the impact of hormonal replacement therapy (HRT) on recurrence rates. Additionally, it outlines surgical indications and addresses dietary factors and non-hormonal treatments under investigation.
This document discusses oncofertility counseling and fertility preservation strategies for young women with breast cancer, emphasizing good clinical practices and assessment checklists for fertility preservation interventions. It highlights the implications of various cancer treatments on fertility and the effectiveness of different preservation methods, along with their impact on disease recurrence and survival rates. The findings suggest that pregnancy after breast cancer treatment remains possible without increased risks, and there is a significant potential for supported fertility outcomes among patients who engage in fertility preservation.
The document discusses various studies and outcomes related to in vitro fertilization (IVF) in patients with endometriosis. It highlights the impact of endometriosis on live birth rates, ovarian response, and the effectiveness of different IVF protocols. Additionally, it notes the need for multidisciplinary approaches and fertility preservation strategies when treating young patients with endometriosis.
This document discusses various applications of artificial intelligence and machine learning in women's health, gynecology, and obstetrics. It provides an overview of supervised and unsupervised machine learning methods such as support vector machines, decision trees, linear regression, logistic regression, naive Bayes, random forests, K-means clustering, and Gaussian mixture modeling. It then discusses several disease applications, including using machine learning for breast cancer diagnosis and risk prediction, osteoporosis risk assessment and fracture prediction, predicting vasomotor symptoms, and using artificial intelligence to aid in the diagnosis of endometrial cancer, cervical dysplasia, and ovarian cancer. Numerous research studies applying these machine learning methods are cited.
This document summarizes various ART options for poor ovarian responders. It discusses criteria for defining poor ovarian response, classification systems like POSEIDON, and studies comparing outcomes of different stimulation protocols. These include mild versus conventional stimulation, different gonadotropin doses and add-backs, natural cycles, estrogen priming, and supplements like DHEA, growth hormone, and CoQ10. Cumulative live birth rates are provided for various patient groups over multiple cycles, showing rates ranging from 12-75% depending on age and ovarian reserve.
The document discusses various studies and findings related to the reproductive outcomes for women over 40, focusing on factors such as fecundability, cumulative pregnancy rates, and live birth rates in relation to age and assisted reproductive technologies. It highlights the diminishing probabilities of natural conception and live birth as age increases, the role of preimplantation genetic testing, and the comparative success rates of IVF treatments. The importance of considering clinical characteristics and treatment approaches in improving outcomes for older women seeking fertility assistance is emphasized.
The document discusses the effects of uterine aging on fertility, hormonal responsiveness, and associated molecular mechanisms in various mammals, particularly focusing on mice and humans. Key findings include reduced pregnancy rates, impaired decidual responses, and changes in gene expression related to aging, which may affect receptivity and fetal development. Additionally, specific genes and signaling pathways involved in age-related dysfunction and inflammation in the uterus are identified, highlighting the complex interplay between aging and reproductive biology.
The document discusses managing menopause and lists its common symptoms such as hot flashes, sleep disturbances, mood changes, and vaginal dryness. It explains that symptoms are more likely during the menopause transition and after menopause as hormone levels decline. The document recommends primary care management of menopause and references algorithms and mobile apps that can help. It provides guidelines on assessing cardiovascular disease risk and reviewing various risk assessment tools.
This document discusses several alternative hormonal treatments for menopause symptoms. It summarizes data from clinical trials on the effects of ospemifene, bazedoxifene, tamoxifen, raloxifene, and prasterone (DHEA) on the endometrium, vagina, breast, bone and other tissues. It finds that these selective estrogen receptor modulators (SERMs) can reduce hot flashes and improve bone mineral density and sexual function symptoms, with neutral or protective effects on the breast and endometrium. Prasterone in particular is shown to significantly improve vaginal dryness, dyspareunia and other symptoms, without increasing serum estrogen, testosterone or DHEA levels
The document discusses evaluation and management of endometriosis. It provides guidelines on suspecting and diagnosing endometriosis based on symptoms. Imaging techniques for diagnosing endometriosis are discussed, including transvaginal ultrasound and MRI. Surgical and medical treatments for endometriosis are covered. Risk of endometriosis recurrence after treatment and risk of endometriosis transforming into ovarian cancer are addressed. Emerging treatments using artificial intelligence and non-hormonal drugs are also mentioned.
The document discusses various machine learning techniques, including supervised and unsupervised learning methods, and their applications in medical diagnoses and health management, particularly in breast cancer and osteoporosis risks. It highlights multiple studies and publications involving artificial intelligence (AI) in predicting disease outcomes and enhancing diagnostic accuracy through advanced algorithms. The content encompasses a broad range of topics related to health data analysis, AI applications in women's health, and ongoing research directions.
This document summarizes management strategies for menopausal symptoms in breast cancer survivors. It discusses pharmacological options like clonidine, oxybutynin, antidepressants, black cohosh, and phytoestrogens. It also covers mind-body practices like cognitive behavioral therapy and hypnosis. Non-hormonal treatments for vulvo-vaginal symptoms are discussed, as well as short-term low dose local estrogen therapy. Management of menopausal symptoms requires a personalized approach balancing symptom relief and safety.
The document discusses the importance of health promotion for healthy ageing and outlines strategies for improving the well-being of older populations. It emphasizes the World Health Organization's definition of 'healthy ageing,' which involves maintaining functional abilities and addressing intrinsic and environmental factors. Key priorities include developing age-friendly environments, strengthening long-term care, and promoting integrated health systems tailored to the needs of older individuals.
Vulvar cancer accounts for about 4% of gynecologic cancers. The most common type is squamous cell carcinoma, which typically affects women ages 65-75. Risk factors depend on whether the cancer is related to HPV infection or vulvar dystrophy. Treatment involves surgical excision, with laser ablation and wide local excision being main options. Topical imiquimod and 5-fluorouracil can also be used to treat preinvasive high-grade lesions. Long-term surveillance after treatment is important due to the risk of recurrence.
Vaginal cancer is most commonly squamous cell carcinoma (SCC) and occurs most often in the 6th and 7th decades of life. Surgical excision is the main treatment for vaginal intraepithelial neoplasia (VAIN). Topical therapies like 5-fluorouracil cream or imiquimod cream can also be used, especially for multifocal disease not involving the lower vagina. Without treatment, 3% of VAIN 1 and 7% of VAIN 2/3 can progress to invasive cancer. Clinical presentation of vaginal cancer may include vaginal discharge, bleeding, urinary or gastrointestinal symptoms depending on location and involvement of nearby organs. Pretreatment evaluation includes examination, imaging, and biopsy